Quantitative Pharmacology Approach to Inform the Bench-to-Bed Translation of CRSPR-Based in-vivo Gene Editing Therapy across Multiple Development Phases
AI-aided Virtual Disease Progression Clinical trials – the marriage of nonlinear mathematical modeling, biology, and AI in predicting future individual patient responses in global health
Dose guidance for a novel combination therapy to treat head and neck squamous cell carcinoma (HNSCC) for patients with HRAS/PIK3CA variants using QSP model
Application of endogenous biomarkers of drug transporters and liquid biopsy coupled with PBPK modelling to support precision dosing in renal impairment
BOAF2 - Harnessing Efficiency in Quantitative Systems Pharmacology (QSP) Modeling: Integrating Workflows, Automation, and Visualization Tools for Enhanced Cross-Functional Communication
Harnessing Efficiency in Quantitative Systems Pharmacology (QSP) Modeling: Integrating Workflows, Automation, and Visualization Tools for Enhanced Cross-Functional Communication
Speaker: Francesco Brizzi, PhD (he/him/his) – Predictive Modelling and Data Analytics, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Switzerland
Speaker: Francesco Brizzi, PhD (he/him/his) – Predictive Modelling and Data Analytics, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Switzerland
Historical borrowing in nAMD: the present as a "prior" for designing more efficient future trials
Location: Canyon Ballroom
Speaker: Francesco Brizzi, PhD (he/him/his) – Predictive Modelling and Data Analytics, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Switzerland
2:40 PM – 3:00 PM MST
Charting New Paths in Ophthalmology with DeepNLME-Powered Predictive Modeling
Panelist: Francesco Brizzi, PhD (he/him/his) – Predictive Modelling and Data Analytics, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Switzerland
Development of a Quantitative Systems Pharmacology Model to Support the Clinical Development of T cell Redirecting Bi- and Tri-specific Antibodies for Patients with Relapsed/Refractory Multiple Myeloma
C3C - Next generation M&S packages deployable and accessible for MIDD and Model Integrated Evidence - Advances Through GDUFA-Sponsored Research
Chair: Yuqing Gong, PhD (she/her/hers) – Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Chair and Speaker: Robert R. Bies, Pharm.D. PhD FISoP – Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo
Speaker: Liang Zhao, PhD (he/him/his) – Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, UCSF
2:00 PM – 3:30 PM MST
Next generation M&S packages deployable and accessible for MIDD and Model Integrated Evidence - Advances Through GDUFA-Sponsored Research
Location: Sonoran Sky Ballroom 5 - 8
Chair: Yuqing Gong, PhD (she/her/hers) – Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Chair and Speaker: Robert R. Bies, Pharm.D. PhD FISoP – Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo
Speaker: Liang Zhao, PhD (he/him/his) – Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, UCSF
2:00 PM – 2:30 PM MST
User-Friendly Tools for Population PK and PBPK Modeling
Location: Sonoran Sky Ballroom 5 - 8
Speaker: Robert R. Bies, Pharm.D. PhD FISoP – Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo
2:30 PM – 3:00 PM MST
Development of A User-Friendly Platform for Model-Integrated Bioequivalence Analysis
Hitting the Sweet Spot: Mechanism-Based Modeling to Evaluate the Interplay of Liver Compound Exposure and Liver Toxicity to Identify Safe Dosing Regimens
A mechanistic model to inform step-up dosing that limits cytokine release following a bispecific T cell engaging antibody treatment for B-cell lymphomas